Could the Shingles Vaccine Also Be Protecting Your Brain?

Here’s a genuinely surprising finding:

A vaccine designed to prevent shingles was associated with a substantially lower risk of dementia.

Researchers studied more than 65,000 people age 65 and older who received two doses of the recombinant zoster vaccine and compared them with more than 263,000 matched unvaccinated people.

Over the study period, the vaccinated group had about a 51% lower observed risk of diagnosed dementia.

That’s a big number.

But there’s an equally important word:

Associated.

The study was observational and retrospective.

Researchers looked at what happened to people who had already received the vaccine rather than randomly assigning people to receive the vaccine or not.

That means the study cannot prove that the vaccine itself prevented dementia.

People who choose vaccination may differ from people who don’t in ways that affect dementia risk.

The researchers tried to address this possibility, including a comparison with people who received a Tdap vaccine, and the association remained statistically significant, although the difference was smaller.

So the finding is intriguing.

But it isn’t proof that the shingles vaccine is a dementia-prevention treatment.

What do we actually know?

The recombinant zoster vaccine is used to prevent shingles and its complications.

The possibility that it might also have an effect on dementia is a separate research question.

It’s an important one—but it’s still a research question.

The Watchdog takeaway

If you’re eligible for shingles vaccination, talk with your healthcare provider about whether you should receive it.

But keep the two ideas separate:

Preventing shingles is an established reason for vaccination.

Preventing dementia is a promising but unproven possibility suggested by this study.

That’s an important difference.